2025-04-18 - Analysis Report
## Eli Lilly and Co (LLY) Stock Review

**0) Key Figures & Initial Analysis:**

Eli Lilly and Co. is a leading pharmaceutical company.  The provided data shows significantly higher returns for LLY compared to the S&P 500 (VOO).  Further analysis is needed to determine the sustainability of this outperformance.

**1) Performance Comparison & Divergence:**

* **LLY Cumulative Return:** 312.35%
* **VOO (S&P 500) Cumulative Return:** 76.18%
* **Return Difference:** 236.2% (LLY outperformed VOO by a substantial margin)
* **Relative Divergence:** 72.0% (This indicates LLY's performance is in the upper 72nd percentile of its historical range relative to the S&P 500.)

The table below shows CAGR (Compound Annual Growth Rate), Maximum Drawdown (MDD), Alpha, Beta, and Market Capitalization (Cap) for LLY over different periods.  LLY consistently exhibits high CAGR and positive alpha, suggesting outperformance compared to the market (Beta > 1 indicates higher volatility than the market).  The increasing market capitalization reflects growth.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 14.0% | 55.9% | -19.0% | 0.1 | 67.7 |
| 2016-2018  | 42.0% | 58.6% | 21.0% | 0.1 | 95.1 |
| 2017-2019  | 55.0% | 58.6% | 21.0% | 1.4 | 110.4 |
| 2018-2020  | 57.0% | 58.6% | 27.0% | 0.7 | 144.7 |
| 2019-2021  | 116.0% | 60.5% | 55.0% | 0.4 | 240.3 |
| 2020-2022  | 111.0% | 64.9% | 102.0% | 0.3 | 322.6 |
| 2021-2023  | 152.0% | 64.9% | 132.0% | 0.3 | 519.2 |
| 2022-2024  | 171.0% | 72.1% | 150.0% | 0.3 | 692.0 |
| 2023-2025  | 144.0% | 76.8% | 130.0% | 0.2 | 754.3 |


**2) Recent Price Movement:**

* **Closing Price:** $839.96
* **5-Day Moving Average:** $763.76
* **20-Day Moving Average:** $787.29
* **60-Day Moving Average:** $830.71

The price is above all three moving averages, suggesting a potential upward trend.  The significant price change of $14.3 indicates recent rapid increase (a sharp jump).


**3) Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.4223 (Medium Risk)
* **RSI:** 52.44 (Slightly above neutral; not overbought)
* **PPO:** 0.57 (Positive, suggesting bullish momentum)
* **20-Day Relative Divergence Change:** +4.2% (Short-term upward trend)
* **Expected Return (vs. S&P 500):** 77.8% over the long term (2+ years). This represents a significant projected outperformance compared to the S&P 500.  This high expected return warrants investigation into the assumptions and potential risks associated with this forecast.

**4) Recent Earnings Analysis:**

| Date       | EPS    | Revenue      |
|------------|--------|--------------|
| 2024-10-30 | $1.08  | $11.44 B     |
| 2024-08-08 | $3.29  | $11.30 B     |
| 2024-04-30 | $2.49  | $8.77 B      |
| 2023-11-02 | -$0.06 | $9.50 B      |
| 2024-10-30 | -$0.06 | $9.50 B      | *(Duplicate entry - likely an error)*

Earnings show some volatility, but generally positive EPS and strong revenue figures.  The duplicate entry should be clarified.


**5) Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue    | Profit Margin |
|---------|------------|---------------|
| 2024-12-31 | $13.53B   | 82.24%        |
| 2024-09-30 | $11.44B   | 81.02%        |
| 2024-06-30 | $11.30B   | 80.80%        |
| 2024-03-31 | $8.77B    | 80.91%        |
| 2023-12-31 | $9.35B    | 80.88%        |

Revenue is growing, and profit margins are consistently high.


**Capital and Profitability:**

| Quarter | Equity     | ROE       |
|---------|------------|-----------|
| 2024-12-31 | $14.19B   | 31.07%    |
| 2024-09-30 | $14.24B   | 6.81%     |
| 2024-06-30 | $13.56B   | 21.88%    |
| 2024-03-31 | $12.81B   | 17.51%    |
| 2023-12-31 | $10.77B   | 20.33%    |

Equity has increased, though ROE fluctuates.  This warrants further investigation to understand the underlying drivers of this variability.


**6) Overall Analysis:**

LLY has shown exceptional performance, significantly outperforming the S&P 500.  The high CAGR, positive alpha, strong revenue growth, and high profit margins suggest a healthy and growing company.  However,  the recent sharp price increase and the volatility in ROE and earnings warrant caution.  Further due diligence is necessary, including a deeper examination of the company's financial statements, future growth prospects, and potential risks.  The high expected return should be critically assessed given the inherent market uncertainties.  The duplicate data entry in the recent earnings needs clarification. A thorough analysis of the assumptions underpinning the 77.8% expected return is crucial before making any investment decisions.
